IndieBio Accelerator

History and Founding Story

IndieBio, established in San Francisco in 2015 by SOSV, pioneered Silicon Valley's first biotech program to integrate on-site bio-labs with pre-seed investment for scientists eager to launch startups. This innovative approach quickly positioned IndieBio as a groundbreaking force in the life sciences and biotech sectors. Over its decade of operation, from 2015 to 2025, IndieBio cultivated a robust ecosystem that supported 310 graduate companies, collectively raising an impressive $3.6 billion. This success solidified SOSV's reputation as a leading investor in health and climate-focused deep tech.

Mission and Values

While the original IndieBio name has transitioned to SOSV NY and SOSV SF as of early 2026, the core mission and values of fostering deep tech innovation remain unchanged. The program's foundational ethos is to empower early-stage scientific ventures, providing them with the necessary resources to translate cutting-edge research into impactful companies. This commitment extends beyond traditional biotech to encompass a broader spectrum of deep tech, including chemistry, physics, AI, and more, reflecting a holistic approach to solving global challenges through scientific entrepreneurship.

Program Structure and Timeline

The program, now operating under the SOSV NY and SOSV SF banners, maintains the same operational excellence and facility infrastructure that defined IndieBio. While specific timelines are not detailed in the provided content, accelerator programs typically run for a fixed duration, often several months, culminating in a demo day or investor showcase. The emphasis is on rapid development, rigorous experimentation, and strategic business planning to prepare companies for subsequent funding rounds and market entry.

Mentorship and Network

Participants benefit from an extensive network cultivated by SOSV, a prominent health and climate investor. This network includes experienced mentors, industry experts, and a community of successful alumni. The hands-on support and guidance from the program's dedicated teams in New York City and San Francisco are crucial for navigating the complexities of scientific entrepreneurship, from R&D to market strategy and fundraising.

Investment Terms

IndieBio, and its successor programs, provide significant early-stage funding. Teams receive $250,000 in seed funding, a critical injection of capital that enables startups to accelerate their research, product development, and team expansion. While the exact equity taken is not specified, such pre-seed investments typically involve a minority equity stake in the participating companies.

What Makes It Unique

IndieBio's uniqueness stemmed from its pioneering model of combining on-site bio-labs with pre-seed investment, a first in Silicon Valley. This integrated approach provided a critical advantage for science-based startups. The evolution to SOSV NY and SOSV SF signifies an expanded focus to all deep tech, demonstrating adaptability and a continued commitment to supporting a wider array of scientifically intensive ventures. The program's proven track record of generating billions in follow-on funding for its graduates underscores its efficacy and impact.

Notable Outcomes

Between 2015 and 2025, IndieBio's 310 graduates collectively raised $3.6 billion in follow-on funding. This impressive figure highlights the program's success in nurturing high-potential companies and preparing them for significant investment. The alumni network spans critical sectors such as food, agriculture, industrial decarbonization, AI, therapeutics, and diagnostics.

What Participants Can Expect Day-to-Day

Participants can expect an intensive, hands-on experience within state-of-the-art lab facilities. The program fosters a collaborative environment where scientific rigor meets entrepreneurial drive. Daily activities likely involve extensive lab work, mentorship sessions, workshops on business development, fundraising, and intellectual property, and regular interactions with the program's expert teams. The goal is to rapidly de-risk scientific hypotheses, develop viable products, and build scalable businesses, all supported by a robust infrastructure and a dedicated community.